Wall Street analysts predict that Natus Medical Incorporated (NASDAQ:NTUS) will announce sales of $124.75 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Natus Medical’s earnings. The lowest sales estimate is $124.50 million and the highest is $125.00 million. Natus Medical reported sales of $130.64 million during the same quarter last year, which would suggest a negative year over year growth rate of 4.5%. The business is scheduled to issue its next earnings report on Wednesday, October 23rd.
According to Zacks, analysts expect that Natus Medical will report full year sales of $497.20 million for the current financial year, with estimates ranging from $496.80 million to $497.60 million. For the next fiscal year, analysts expect that the firm will report sales of $509.70 million, with estimates ranging from $509.40 million to $510.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Natus Medical.
Natus Medical (NASDAQ:NTUS) last released its earnings results on Thursday, July 25th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.04. Natus Medical had a positive return on equity of 10.73% and a negative net margin of 7.38%. The firm had revenue of $125.54 million for the quarter, compared to analyst estimates of $122.85 million.
NASDAQ:NTUS traded up $0.61 during mid-day trading on Monday, hitting $30.88. The company had a trading volume of 166,100 shares, compared to its average volume of 252,531. Natus Medical has a fifty-two week low of $22.25 and a fifty-two week high of $37.45. The company has a current ratio of 1.93, a quick ratio of 1.36 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 21.75 and a beta of 0.63.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.